Keyphrases
Israel
100%
COVID-19
64%
BNT162b2 Vaccine
47%
Neutralizing Antibodies
43%
BNT162b2
37%
Immunogenicity
34%
Healthcare Workers
31%
West Nile Virus
28%
Receptor-binding Domain
24%
Third Dose
24%
Vaccination
22%
Humoral Response
21%
Travellers
21%
IgG Antibody
21%
Vaccine Dose
21%
COVID-19 Vaccine
19%
Zika Virus
19%
Israeli
18%
Antibody Response
16%
Immune Response
15%
Seroprevalence
14%
Second Dose
13%
Confidence Interval
12%
Dengue
12%
Omicron Variant
11%
Antibody Titer
11%
Adverse Events
11%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Dengue Virus
10%
Zika Virus Infection
10%
West Nile Virus Infection
10%
SARS-CoV-2 Infection
10%
Geometric Mean Titer
10%
Seropositivity
9%
Immunoglobulin G Antibodies
9%
Quantitative PCR
9%
BNT162b2 COVID-19 Vaccine
9%
Liver Transplant Recipients
9%
Virus RNA
9%
COVID-19 Vaccination
9%
Breakthrough Infection
8%
Dengue Infection
8%
Zika
8%
Prospective Cohort Study
8%
Two-dose
8%
Human Infection
8%
Signal Recognition Particle
8%
Immunoglobulin G
7%
Antireceptor
7%
Viral Outbreaks
7%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
71%
COVID-19
61%
Neutralizing Antibody
42%
Receptor Binding
26%
West Nile Virus
23%
Antibody Response
22%
Omicron Coronavirus Variant
22%
Humoral Immunity
22%
Immunogenicity
20%
Neutralization
19%
Antibody Titer
19%
Dengue Fever
19%
Titer
16%
Immunoglobulin G
13%
Immune Response
13%
Spike
13%
Immunoglobulin G Antibody
12%
Viral Disease
10%
Seroprevalence
9%
Breakthrough Infection
9%
Virus
8%
Serology
8%
Seropositivity
8%
Wild Type
7%
Trypanosoma Brucei
7%
T Cell
7%
Booster Dose
7%
RNA Interference
7%
Cladistics
6%
Dengue Virus
6%
Lineages
6%
Enzyme-Linked Immunosorbent Assay
6%
Cross-Reactivity
6%
RNA Virus
6%
Prevalence
6%
Zika Virus
5%
Trypanosoma
5%
Flavivirus
5%
RNA Vaccine
5%